Alaunos Therapeutics, Inc. — Form 8-K Summary
Reporting date: October 22, 2026 (the report was signed October 23, 2026). The filing reports a Nasdaq listing update; it is not a periodic financial-results report.
Business context and key development
Nasdaq confirmed on October 22 that Alaunos had regained compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq closed the matter, cancelled the November 10 hearing, and said the company’s common stock would continue to be listed and traded on the exchange. The company attributed its expected return to compliance to a private placement completed October 14, 2026.
Financial information
This filing provides no revenue, profit or loss, cash flow, margin, debt, liquidity, financing amount, or other current-period financial figures. It does not quantify stockholders’ equity after the private placement.
Material change and risks
The company had received an initial noncompliance notice on April 9, 2026, and a delisting notice on October 5. The October 22 Nasdaq confirmation resolves that specific deficiency, but does not assure ongoing compliance with all Nasdaq requirements. The company identifies risks including operating losses and transaction costs reducing equity; preliminary accounting conclusions about preferred-stock classification changing during the financial-statement close or auditor review; obtaining contemplated stockholder approvals; and failing to demonstrate compliance when filing its 2026 Form 10-K, which could lead to delisting.
Investor verification points
- Review the private placement terms and its effect on stockholders’ equity; this filing does not state the financing amount or resulting equity balance.
- Check subsequent filings for completion of the financial-statement close and any change in preferred-stock accounting treatment.
- Verify whether the contemplated stockholder approvals were obtained and whether the company satisfies other Nasdaq listing requirements, including when it files its 2026 Form 10-K.